Published in Blood Weekly, November 14th, 2002
The study will test for the presence of urinary fibrinopeptide B (FPB) as a marker for active VTE, as well as a tool to monitor the effectiveness of anticoagulant therapy. Preliminary studies and data have confirmed that urine FPB levels can be used to screen patients with suspected VTE and to monitor patients following treatment.
The company has exclusive commercialization rights...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.